Medical Developments International Ltd.’s (ASX:MVP) stock traded around $4.10, as at August 08, 2018, mid-day trading, with a daily price change of 1.49%. The annual dividend yield for the stock is 0.99% which is fully franked. The most recent dividend declared is 2c with dividend ex-date as March 02, 2018 and dividend pay-date as April 13, 2018. Over the past one year, the stock has fallen significantly. Primarily, FDA has put the approval for clinical program for Penthrox for sale in the USA on hold and a letter outlining outstanding issues and concerns is to be issued, as advised by the FDA. For more than 30 years in Australia and with more than 6.0 million units sold, Penthrox has been used safely and effectively. The group has lately proceeded with placement of 4,250,000 ordinary shares raising $17 million from investors at a price of $4.00 per share while the FY18 result update has not been very encouraging with fall slated for revenue and net profit after tax.
Osprey Medical Inc (ASX:OSP), is the medical device group that develops technologies to protect kidneys from dyes etc. It has revealed that since the time of first revenues reported by the group, OSP has now witnessed a 15th consecutive quarter of growth. The total addressable market for DyeVert and new product DyeTect is US$1.8 billion. Invested in Osprey’s success is the top tier board and management team. As compared to Q2 2017, there has been a 60% revenue growth in Q2 2018. 43% increase in new hospitals purchasing year over year with 28 hospitals at the end of Q2 2018 in the sample to purchase process, has also been reported. The stock was trading at a market price of $0.24 as at August 8, 2018 before market close.
Oncosil Medical Limited (ASX:OSL) is another health care medical device company based out of Sydney and focusing on oncology. The stock was trading at a market price of $0.20 as at August 08, 2018 (intra-day trading) and has seen a performance change of over 100% over the past 12 months. For pancreatic cancer, the company is commercializing a break through implantation radiation treatment; and is targeting more than $2bn market opportunity to improve standard of care. Manufacturing and logistics have been optimized for supply of commercial quantities. U.S. FDA-approved IDE is in place and safety run-in is underway; then CE Marking is expected in near-term. The group has a highly experienced management team; strong clinical and commercial pedigree.
Ellex Medical Lasers Limited (ASX: ELX) is a medical devices manufacturer dealing in eye diseases, and the group saw its stock plunging by 1.35% during intra-day trading at a market price of $0.73 on August 08, 2018. The stock has seen a performance change of -24.37% over the past 12 months. The group has now seen a sales growth of 13% to A$79.1 million as compared to the prior year. The group has also reported higher sales for its largest market, the USA.
Avita Medical Limited (ASX:AVH), a medical technology company targeting the regenerative medicine and respiratory markets, has presence in Asia-Pacific region, Europe, Middle East and Africa (EMEA) and the Americas. The stock of the group was trading at a market price of $0.084 on August 08, 2018 before market close. During the quarter ended 30 June 2018, total net cash used in operating activities, was up 42% compared to the prior quarter. The group had planned for U.S. launch of lead product RECELL® (therapy for skin regeneration) for CY 2018.
These stocks are key to look at, however, few groups with successful developments such as Oncosil do stand a chance for growth.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.